Pancreatic and Hepatic Oncology Research

Pancreatic and hepatic cancers rank among the most lethal malignancies, largely because they are rarely detected before the disease has spread and respond poorly to standard treatments. Researchers study the full arc of the problem, from the dense stromal tissue surrounding pancreatic tumors that limits drug delivery, to genomic alterations driving disease progression, to the optimization of chemotherapy regimens like gemcitabine and neoadjuvant strategies intended to shrink tumors before surgery. A central open question is how the tumor microenvironment suppresses immune responses and whether remodeling that environment can make immunotherapy viable for patients who currently derive little benefit from it. At the same time, investigators are examining how surgical volume, technique, and complication management affect survival, recognizing that even patients who reach resection face steep perioperative risks.

Works

146,789

Total citations

2,119,755

Keywords

Pancreatic CancerSurgical ComplicationsGemcitabineTumor MicroenvironmentGenomic AnalysesChemotherapy